anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The creating medical investigation picture of liver (1) of a patient for investigating- and/or treatment of the liver, comprises injecting water soluble iodine containing solution into the liver, creating a three dimensional (3-D) image of the liver, depicting a catheter on the 3D image to dispense the water soluble iodine containing solution visible on the 3-D-image, and computing the 3-D images from a series of X-ray radiography images. The 3-D image and the generated radioscopy X-ray image are registered and are represented with one another. The creating medical investigation picture of liver (1) of a patient for investigating- and/or treatment of the liver, comprises injecting water soluble iodine containing solution into the liver, creating a three dimensional (3-D) image of the liver, depicting a catheter on the 3-D image to dispense the water soluble iodine containing solution visible on the 3-D-image, and computing the 3-D images from a series of X-ray radiography images. The 3-D image and the generated radioscopy X-ray image are registered and are represented with one another. The position of the catheter is detected by an electromagnetic orientation system. The detected position of the catheter is faded in the 3-D-image. The medical investigation picture is created during the implantation of a transjugular intrahepatic portosystemic stent shunts (TIPSS) (4). An independent claim is included for X-ray radiography plant for creating two-dimensional and three dimensional investigation picture of the liver of a patient.
In mammals, the ventral respiratory column (VRC) plays a pivotal role in integrating neurochemically diverse inputs from brainstem and forebrain regions to generate respiratory motor patterns. VRC microinjection of the neuropeptide galanin has been reported to dampen carbon dioxide (CO2)-mediated chemoreflex responses. Additionally, we previously demonstrated that galaninergic neurons in the retrotrapezoid nucleus (RTN) are implicated in the adaptive response to hypercapnic stimuli, suggesting a link between RTN neuroplasticity and increased neuronal drive to the VRC. VRC neurons express galanin receptor 1, suggesting potential regulatory action by galanin, however, the precise galaninergic chemoreceptor-VRC circuitry remains to be determined. This study aimed to identify sources of galaninergic input to the VRC that contribute to central respiratory chemoreception. We employed a combination of retrograde neuronal tracing, in situ hybridisation and immunohistochemistry to investigate VRC-projecting neurons that synthesise galanin mRNA. In an additional series of experiments, we used acute hypercapnia exposure (10% CO2, 1 h) and c-Fos immunohistochemistry to ascertain which galaninergic nuclei projecting to the VRC are activated. Our findings reveal that a total of 30 brain nuclei and 51 subnuclei project to the VRC, with 12 of these containing galaninergic neurons, including the RTN. Among these galaninergic populations, only a subset of the RTN neurons (approximately 55%) exhibited activation in response to acute hypercapnia. Our findings highlight that the RTN is the likely source of galaninergic transmission to the VRC in response to hypercapnic stimuli.
Pathogenic heterozygous loss of function variants in CTNNB1 are associated with CTNNB1 neurodevelopmental disorder. We report the clinical phenotype of individuals with CTNNB1 neurodevelopmental disorder using both caregiver-reported data (medical history, adaptive function, quality of life, and behavior issues) and in-person clinical assessments (neurological, motor, and cognitive function) in 32 individuals with likely pathogenic or pathogenic CTNNB1 variants. Most individuals had truncal hypotonia, muscle weakness, hypertonia, dystonia, microcephaly, and many had a history of tethered cord. Visual problems included strabismus, hyperopia, and familial exudative vitreoretinopathy. Half of individuals walked without an assistive device. The mean Gross Motor Functional Measure-66 score was 56.6 (SD = 14.8). Average time to complete Nine-Hole Peg Test was slower than norms. Mean general conceptual ability composite scores from Differential Ability Scales Second Edition were very low (M = 58.3, SD = 11.3). Fifty-five percent of individuals had low adaptive functioning based on the Vineland Adaptive Behavioral Scales. Based upon the Child Behavior Checklist total problems score, the majority (65%) of individuals had behavioral challenges. The mean overall Quality of Life Inventory-Disability score was 81.7 (SD = 11.9). These data provide a detailed characterization of clinical features in individuals with CTNNB1 neurodevelopmental disorder.
Flumazenil does not consistently reverse amnesia. Patients cannot be expected to remember information told to them in the postprocedure period and instructions given to patients should be reinforced in writing or given to a responsible family member. Physicians are advised to discuss with patients or their guardians, both before surgery and at discharge, that although the patient may feel alert at the time of discharge, the effects of the benzodiazepine (e.g., sedation) may recur. As a result, the patient should be instructed, preferably in writing, that their memory and judgment may be impaired and specifically advised:

  1. Not to engage in any activities requiring complete alertness, and not to operate hazardous machinery or a motor vehicle during the first 24 hours after discharge, and it is certain no residual sedative effects of the benzodiazepine remain.
  2. Not to take any alcohol or non-prescription drugs during the first 24 hours after flumazenil administration or if the effects of the benzodiazepine persist.
The intervention group will use two Winix 5500-2 HEPA filtration units (Appendix A) (https://winixamerica.com/product/5500-2/). One will be placed in the child's sleep space and one will be placed in another common room with both units running continuously on the "high" (i.e., level 3 / second from highest) setting. Each unit is 8.2 x 15.0 x 23.6 inches, and verified for a 360 sq. foot room. If a home is too small to accommodate 2 Winix units (for example, a single room residence'), one Winix unit may be used for the study. Additional features beyond HEPA and carbon filter, include plasmawave technology to reduce volatile organic compounds and odors. The plasmawave feature will be turned off to avoid ozone production.
The invention provides a traditional Chinese medicine composition for preventing and treating honeybee microsporidiosis. The traditional Chinese medicine composition comprises polygonum cuspidatum and szechwan chinaberry fruit aqueous extract products according to a volume ratio of 1: 1. The traditional Chinese medicine composition and sugar syrup with a concentration of 60-70% by mass are processed to form medicine-containing syrup with a concentration of 4-13% according to a certain volume ratio, and the medicine-containing syrup is freely eaten by honeybees suffered from honeybee microsporidiosis. Through action on honeybees and microsporidia, the traditional Chinese medicine composition can prevent and treat honeybee microsporidiosis. The traditional Chinese medicine composition reduces toxicity of szechwan chinaberry fruit in a single agent, has parasite expelling effects of szechwan chinaberry fruit and anti-inflammation and detumescence effects of polygonum cuspidatum and has basically no toxicity. The traditional Chinese medicine composition utilizes easily available medical raw materials with a wide source, can be prepared simply and has a low cost. The traditional Chinese medicine composition does not produce drug residue on honeybee products and the environment and does not pollute human and animals and the environment. The traditional Chinese medicine composition can be used in drugs for prevention and treatment on honeybee microsporidiosis.
BACKGROUND: Intraindividual differences between estimated glomerular filtration rate (eGFR) based on cystatin C (eGFRcys) and creatinine (eGFRcr) can convey important clinical information regarding health status. However, the clinical implications of these differences (eGFRdiff) for risk of cognitive decline and motoric cognitive risk (MCR) syndrome remains unclear. We aimed to investigate the longitudinal associations of eGFRdiff with cognitive trajectories and incident MCR.
METHODS: Based on the China Health and Retirement Longitudinal Study, we identified two study subcohorts: one for cognitive trajectory follow-up (6423 participants, 2011-2018) and another for incident MCR follow-up (2477 participants, 2011-2015). The eGFRdiff was defined as eGFRcys - eGFRcr. Adjusted ordinal and binary logistic regression models were separately used to assess the associations of eGFRdiff with cognitive trajectories and incident MCR. We also performed discordance analyses for eGFRdiff versus eGFRcys, eGFRcr or eGFR based on both creatinine and cystatin C (eGFRcys-cr).
RESULTS: In the first subcohort, four distinct 7-year cognitive trajectories were identified. Each 1 standard deviation (SD) higher eGFRdiff (value for eGFRcys - eGFRcr) was associated with a lower risk of poorer cognitive trajectories {odds ratio 0.909 [95% confidence interval (CI) 0.877-0.942]}. In the second subcohort, 121 participants developed incident MCR after a 4-year follow-up. Each 1-SD higher eGFRdiff (value for eGFRcys - eGFRcr) was linked with a 25.3% (95% CI 16.6-33.2) decreased risk for MCR. The above associations persisted in individuals with normal kidney function. Additionally, the risk for cognitive decline and incident MCR was more strongly associated with eGFRcys than eGFRcr and eGFRcys-cr. For the discordance analyses, the 'discordantly high eGFRdiff/low eGFR' group but not the 'discordantly low eGFRdiff/high eGFR' exhibited a significantly lower risk of poorer cognitive trajectories and MCR compared with the concordant group.
CONCLUSIONS: A large negative difference between eGFRcys and eGFRcr (eGFRcys < eGFRcr) was associated with a higher risk of cognitive decline and incident MCR. The eGFRdiff could capture additional valuable risk information beyond eGFRcys, eGFRcr and eGFRcys-cr.
Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.

Metoprolol is a beta 1-selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2-adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction. 

The relative beta 1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta 2-mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine. (2) In asthmatic patients, metoprolol reduces FEV 1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta 1-receptor blocking doses. 

The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation. Using an E max model, the maximum effect is a 30% reduction in exercise heart rate, which is attributed to beta 1-blockade. Beta 1-blocking effects in the range of 30 to 80% of the maximal effect (approximately 8 to 23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30 to 540 nmol/L. The relative beta 1-selectivity of metoprolol diminishes and blockade of beta 2-adrenoceptors increases at plasma concentration above 300 nmol/L. 

Although beta-adrenergic receptor blockade is useful in the treatment of angina, hypertension, and heart failure there are situations in which sympathetic stimulation is vital. In patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. In the presence of AV block, beta-blockade may prevent the necessary facilitating effect of sympathetic activity on conduction. Beta 2-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to bronchospasm and may also interfere with exogenous bronchodilators in such patients. 

In other studies, treatment with metoprolol succinate extended-release produced an improvement in left ventricular ejection fraction. Metoprolol succinate extended-release was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.
Systems and methods are provided to supplement an electronic record with additional information related to the electronic record. The additional information is provided to the user of the electronic record as a banner, ribbon or pop-up window that overlays or “floats” over the electronic record. The user can interact with the ribbon to obtain the additional information or ignore the ribbon and the ribbon can be hidden automatically. The ribbon can be launched in response to the user accessing a specific screen or page of the electronic record. The ribbon can provide the user with the additional information that is related to the current screen or page of the electronic record. The additional information can include information obtained from other sources that is not part of the electronic record and calculations and metrics that are not part of the electronic record.
A method of establishing collaborative breeding parameters using blockchain technology is provided. The method may include providing a first user and a second user. The first user may own a first UIAM (unique identity asset marker) token corresponding to a first genomic asset and the second user may own a second UIAM token corresponding to a second genomic asset. The method may further include providing the first and second UIAM tokens and receiving a Ricardian contract with terms governing ownership rights for offspring. The Ricardian contract may be digitally executed and published on at least one blockchain. The method may further include minting a third UIAM token corresponding to a first offspring of the first and second genomic assets to the at least one blockchain. The third UIAM token may reflect the terms of the Ricardian contract and may evidence lineage of both the first and the second UIAM tokens.
Subjects in single vision lens group will receive a pair of single vision lenses for the first year of study. They will then receive a pair of DG2 lenses for the second year of the study.
<P>PROBLEM TO BE SOLVED: To prepare a supplement composed mainly of vitamins.  <P>SOLUTION: A prescribed amount of a liquid containing an ionized mineral is added to a vitamin-containing main material to obtain the supplement bonded with the ionized mineral. Preferably, a powdery main material containing the vitamin is incorporated with the liquid containing 0.1-50.0 wt.% ionized mineral and the mixture is finely divided. The finely divided main material is kneaded with an oil and the obtained viscous mixture is sealed in a capsule to obtain the supplement. The supplement bonded with the ionized mineral is effective for promoting the absorption of and increasing the bioavailability of the vitamins.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Women with breast cancer who will receive adjuvant treatment for the first time, who agree to participate in the study, will be pre-tested before chemotherapy and a post-test will be performed 30 minutes after the start of chemotherapy treatment by the nurse. This follow-up will be done 3 more times, and each cure will be followed for 4 cures. It will be ensured that the patients fill out the State Anxiety Scale and Cancer Fatigue Scale as a pre-test and post-test.
Patients receive buparlisib PO QD on days 1-28 and ofatumumab IV on days 1, 8, 15, and 22 during of courses 1-2; and day 1 of courses 4-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
There is a small but critical window of dietary zinc intake from 1 to 4 mg Zn/day over which the symptoms of long-term zinc deficiency go from acute to chronic in nature. For example, at 1 mg Zn/day intake for several months, most people will develop skin lesions, but at 4 mg Zn/day, skin lesions would be very rare. However, impaired immune response can be detected when consuming zinc up to 6 mg/day over several months. Dietary intakes of \<4 mg Zn/day in developed countries is rare but can be common in developing countries.

This study has been carefully designed to test the hypothesis that consumption of zinc biofortified potatoes can rescue the zinc status and health of people who are of low zinc status and consuming diets which are borderline acutely zinc deficient. The protocol for the study includes 2 weeks of zinc deprivation at around 1 mg Zn/day dietary intake (Very Low Zinc Diet) followed by 2 weeks of a borderline acutely/chronically deficient diet of around 4-5 mg Zn/day (Low Zinc Diet). Two weeks on the Very Low Zinc Diet has been carefully and deliberately selected to cause biochemical changes due to zinc deprivation but not signs and symptoms of deficiency such as skin lesions. Less than 2 weeks is insufficient to cause the biochemical effects and more that 2 weeks risks the physical manifestation of deficiency and also non-compliance by volunteers, since the diets may be less palatable than their habitual diet. Thus all volunteers will have low zinc status at the time of starting to eat the Low Zinc Diet, and the effect of eating the biofortified potatoes in addition, which will add an extra 1 mg to the daily zinc intake, should be seen in all the zinc and health status tests that the investigators are proposing. In rat studies in which the investigators did just this kind of intervention, the biofortified potato ameliorated the effect of zinc deficiency on growth, food intake and immune function.
Single arm trial where all patients will be treated with afatinib until the day of surgery and for a minimum of two weeks. Patients will receive treatment with afatinib 40mg orally daily.
BACKGROUND: In the context of rheumatoid arthritis and its systemic inflammatory implications, there is an increasing interest in investigating the role of prolactin in the clinical and metabolic aspects of the disease. This study aimed to explore the potential links between serum prolactin levels, serum glucose levels, and the clinical manifestations of arthritis.
METHODS: This exploratory, cross-sectional, observational study focused on women diagnosed with rheumatoid arthritis. The research involved assessing prolactin and blood glucose concentrations, alongside specific clinical traits such as disease-related inflammation, morning stiffness, and fatigue intensity. The presence of changes in serum prolactin (PRL) was initially compared among the groups based on disease activity intensity. Using a multinomial regression analysis, the study analyzed the impact of predetermined clinical and metabolic factors on various categories of prolactin concentration.
RESULTS: Out of the 72 participants included in the study, hyperprolactinemia was detected in 9.1% of the sample. No differences in serum PRL were identified among the evaluated groups based on disease activity. Following multivariate analysis, no statistically significant differences were identified for the outcomes of inflammatory activity and morning stiffness within each PRL category when compared to the reference category for PRL. There was no increased likelihood of encountering blood glucose levels below 100 mg/dl among individuals with higher prolactin concentrations compared to those in the lowest prolactin category (OR 5.43, 95% CI 0.51-58.28). The presence of clinically significant fatigue revealed a higher likelihood of encountering this outcome among patients with intermediate PRL values (prolactin categories 7.76-10.35 with OR 5.18, 95% CI 1.01-26.38 and 10.36-15.29 with OR 6.25, 95% CI 1.2-32.51) when compared to the reference category.
CONCLUSIONS: The study found no discernible correlation between prolactin concentrations and worse scores for inflammatory activity of the disease, nor between prolactin concentrations and serum glucose levels. The findings regarding fatigue should be approached with caution given the exploratory nature of this study.
HIPEC with Docetaxel/ Lobaplatin at the time of fist surgery and twice repeat within one week after the surgery, following 2 cycles of 3-week Oxaliplatin/S1 chemotherapy combined with Apatinib and 1 cycles of 3-week Oxaliplatin/S1 chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
The invention relates to a dihydroartemisinin and Chinese blister beetle composition, an enteric preparation and an application and a preparation thereof. The composition mainly comprises the materials in part by weight as follows: 5-20 parts of dihydroartemisinin, 0.1-0.5 parts of sodium cantharidate and 5-15 parts of vitamin B6. The enteric preparation comprises a chip and an enteric coating. The composition and auxiliary materials are prepared into the chip and the enteric coating to obtain the enteric preparation. The dihydroartemisinin and Chinese blister beetle composition and the enteric preparation prepared treat cancers and improve immunity, and have good curative effect in treatment of various cancers such as cancer of the liver, lung cancer and ovarian cancer and the like. The enteric preparation releases medicines in the intestinal tract, avoids stomach irritation and toxicity, and improves the absorptivity.
High-risk for lung cancer population who meet the USPSTF eligibility. One 10-L breath sample will be collected from each subject. During breath collection, subjects will be asked to exhale into a portable breath sampling device through a single use filter. Subjects will not be contacted to donate additional/serial breath specimens after the initial breath samples. Subjects will fill out a medical questionnaire and medical records will also be reviewed to extract low-dose CT scan (LDCT) screening results and any additional tumour-related information including histologic subtype, tumor stage, and sites of disease.